Landos Biopharma Provides Company Update and Reports Third Quarter 2023 Results
Provided By GlobeNewswire
Last update: Nov 9, 2023
NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Remains On Track with Top-line Results Planned for Q4 2024
Sufficient Cash to Fund Planned Operations into First Half of 2025
Read more at globenewswire.com
